Yifan Pharmaceutical Co., is an A share company
listed at Shenzhen Stock Exchange under the security company name of Yifan
Pharm and Ticker Symbol of 002019.
As a pharmaceutical company focusing on innovation,
R&D, and manufacturing, Yifan has established Central R&D Center,
national post-doctorate scientific research center and provincial technology
center (research & development center), has acquired a number of high-tech
enterprises, employs over one hundred professionals with pharmacology related
masters or doctorate degrees, owns two leading edge technologies (DiKineTM and
ITabTM ), holds over 90 international and domestic patents.
Yifan participates the National “Tenth Five-Year
Plan” Key Projects, National High Tech Industrialization Demonstration Projects
and National Torch Projects; has received both the second prize of National
Invention and National Technology Progress.
Yifan leverages its expertise, specialization and product
portfolio in target therapeutic areas as guidance, continuously innovating,
transformatively upgrading, focusing on biologics, high-end small molecule
drug, special Traditional Chinese Medicine, and other key therapeutic areas.
Research pipeline includes tens of small molecule drugs, ten of which are at clinical
or ANDA application stages, holds over 400 approval numbers for marketing of
drugs in therapeutic areas of gynecology, pediatrics, dermatology, etc. 40 of
these drugs are exclusive to the company, and 20 of which are covered by
national health insurance. Several biological drugs are in global phase II and
III studies. Yifan is the first Chinese pharmaceutical enterprise that has
innovative biological drugs in US phase II and phase III studies, bringing
Chinese biologics to knock on America’s door.
Yifan has already formed manufacturing center for
high-end small molecules and plant based medicines in Anhui Province, manufacturing
center for dermatological and gynecological products in Sichuan Province, manufacturing
center for orthopedics drug and infusion in Liaoning Province, R&D and
manufacturing centers for biologics in Beijing and Shanghai and API
manufacturing center in Zhejiang.
Besides Hong Kong, Macau and Taiwan, Yifan’s
pharmaceutical business covers more than 60% of class II and III hospitals in
all provinces and cities in China. As one of the largest manufacturer and
supplier of calcium pantothenate, sales network of API covers Europe, US, and
other global regions, and takes 40% -45% of global market share.
Yifan will constantly focus on pharmaceutical and
healthcare industry, adhere to the development strategy of “integration,
innovation, and globalization”, believe the core value of “pragmatism, innovation, honesty, and diligence”, commit ourselves to deliver benefit to customer, create
development platform for employee, achieve return for shareholders, create
value for society, and continue to grow as the expert of global pharmaceutical
and healthcare industry.